Caffeic acid derivatives block NF-κB activation (7), and it has been hypothesized that NF-κB inhibitory molecules are clinically beneficial as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematological malignancies (14). This evidence concerns the gene NFKB1 and hematologic disorder.